Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2014) 35 P597 | DOI: 10.1530/endoabs.35.P597

1Endocrinology and Nutrition Unit, Virgen Macarena University Hospital, Sevilla, Spain; 2Oncology Unit, Virgen Macarena University Hospital, Sevilla, Spain.

Introduction: Everolimus is a drug selective inhibitor of mTOR. In 2012 a Phase 2 study* of everolimus monotherapy demonstrated modest efficacy in patients with pheochromocytomas/paragangliomas. Our objective was to evaluate the efficacy and safety of everolimus in a patient with paraganglioma. (*Phase 2 study of everolimus monotherapy in patient with nonfunctioning neuroendocrine tumor or pheochromocytomas/paraglangliomas. Do-Young Oh et al. Cancer 2012 15 6162–6170).

Clinical case: We present a 29 years old man with recent arterial hypertension diagnosis (triple therapy), vomiting, and weight loss. A scan study shows left para-aortic retroperitoneal mass of 7.4×8.5×8 cm involving the celiac trunk, superior mesenteric artery and left renal hilum. The cytology result by endoscopic ultrasound was spindle cell tumor, suspected of gastrointestinal stroma tumor (GIST). The pathological diagnosis after biopsy exploratory laparotomy was infiltration by paraganglioma. A metaiodobenzylguanidine scintigraphy show patholocical uptake in retroperitoneal mass, 9th right rib and left iliac bone, with great elevation of urinary catecholamines (normetanephrine: 12.832 μg/24 h; dopamine: 1.345 μU/24 h). The patient was treated with 131I-MIBG, 200 mCi by i.v. infusion. A CT control showing progression of disease with high catecholamines (normetanephrine: 18.140 μg/24 h; dopamine: 1.944 μU/24 h). We tried treatment with cyclophosphamide, vincristine and dacarbazine (CVD) in cycles every 21 days with a partial response by CT and biochemical monitoring (normetanephrine: 11.325 μg/24 h; dopamine: 830 μU/24 h). However the treatment was suspended after the second cycle for severe toxicity (ventricular systolic dysfunction severe, hepatolisis, neutropenia, anemia, thrombocytopenia and refractory hypertension). In this moment we started treatment with everolimus (10 mg/24 h). After ten treatment cycles the disease has remained stable (normetanephrine: 8.706 μg/24 h; dopamine: 737 μU/24 h) with good blood pressure control and improvement of pain. No important side effects were observed.

Conclusions: In cases of pheochromocytomas/paragangliomas with severe toxicity after treatment by chemotherapy CVD, everolimus in monotherapy keep the response with good tolerance, so it may be a good treatment option in this cases.

Article tools

My recent searches

No recent searches.